Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
NA
20 participants
INTERVENTIONAL
2026-01-01
2029-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main question
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
High-Dose RT
27Gy in 3 fractions with boost
Palliative Radiotherapy
high-dose RT
Standard Dose Palliative RT
24Gy in 3 fractions
Palliative Radiotherapy
standard dose RT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Palliative Radiotherapy
standard dose RT
Palliative Radiotherapy
high-dose RT
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age 18 or older.
* Able to provide informed consent
* Patient has histologically confirmed solid tumour malignancy
* ECOG performance status 0 - 2
* Life Expectancy \> 6 months
* 1-5 target lesions larger than 5cm
* A history and physical exam, including ECOG performance status, performed within 6 weeks prior to trial enrollment
* Not suitable for or declined curative-intent treatment
* Subject has had a CT neck, chest, abdomen and pelvis or PET-CT within 8 weeks prior to enrollment, and with 12 weeks of treatment
* MRI spine for patients receiving RT to vertebral or paraspinal metastases
* Patient is judged able to:
* Maintain a stable position during therapy
* Tolerate immobilization device(s) that may be required to deliver radiation safely
Exclusion Criteria
* Disease limited to intracranial sites
* Serious medical co-morbidities precluding radiotherapy
* Bone metastases with no soft tissue component
* Prior radiation to target lesion that precludes delivery of repeat radiation. All such cases should be discussed with the local and study PIs.
* Pregnant women
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
British Columbia Cancer Agency
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Wei Liu, MD, FRCPC
Role: PRINCIPAL_INVESTIGATOR
BC Cancer - Vancouver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
BC Cancer - Vancouver
Vancouver, British Columbia, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Sandy Chang
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Hi-D
Identifier Type: -
Identifier Source: org_study_id